生长抑素治疗肝硬化并发门静脉血栓的临床研究  

Clinical Study of Somatostatin in the Treatment of Cirrhosis Complicated with Portal Vein Thrombosis

作　　者：赵静[1] 王慧超[1] 葛相栓[1] 张改玲[1] ZHAO Jing;WANG Huichao;GE Xiangshuan(Henan Hongli Hospital Department of Gastroenterology,Henan Xinxiang 475000)

机构地区：[1]河南宏力医院消化内科,河南新乡475000

出　　处：《航空航天医学杂志》2020年第2期142-144,共3页Journal of Aerospace medicine

摘　　要：目的探究生长抑素治疗肝硬化并发门静脉血栓(PVT)的临床疗效。方法选取2015年4月-2018年7月收治的肝硬化并发PVT的患者96例作为研究对象,根据治疗方式的差异将患者分为观察组与对照组,各48例。对照组接受常规西药治疗,观察组在此基础上联用奥曲肽进行治疗,对比两组患者在治疗后各项观察指标间的差异。结果治疗后观察组患者ALT、AST、TBIL水平均明显低于对照组,ALB水平明显高于对照组,各项对比结果均表现出显著差异(P<0.05);观察组PT、PVD内径均明显低于对照组,FIB、PLT水平均明显高于对照组,各项对比结果均表现出显著差异(P<0.05)。结论生长抑素在肝硬化并发PVT患者的治疗中表现出较好的效果,疗效比一般的西药治疗更加显著。Objective To explore the clinical effect of somatostatin in the treatment of cirrhosis complicated with portal vein thrombosis(PVT).Methods 96 patients with cirrhosis complicated with PVT admitted in our hospital from April 2015 to July 2018 were selected as the research objects.According to the difference of treatment methods,the patients were divided into observation group and control group,48 cases each.The control group received symptomatic support treatment,and the observation group was treated with octreotide on this basis,to compare the differences between the two groups after treatment.Results After treatment,the levels of alt,AST and TBIL in the observation group were significantly lower than those in the control group,and the levels of Alb were significantly higher than those in the control group,with significant differences in the comparison results(P<0.05);the inner diameters of Pt and PVD in the observation group were significantly lower than those in the control group,and the levels of FIB and PLT were significantly higher than those in the control group,with significant differences in the comparison results(P<0.05).Conclusions somatostatin has a better effect in the treatment of cirrhosis complicated with PVT,and the effect is more significant than that of Western medicine.

关 键 词：生长抑素 肝硬化 门静脉血栓 奥曲肽 疗效 

分 类 号：R575.21[医药卫生—消化系统]